Kalehua Capital Management LLC
CIK: 0002106181Latest portfolio: $101.1M · Q4 2025
Holdings
19
Total Value
$101.1M
New Positions
19
Closed Positions
0
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | BOXXAlpha Architect 1-3 Month Box Etf | 230,787 | $26.6M | 26.27% | |
| 2 | XFORX4 Pharmaceuticals Inc | 3,722,840 | $14.9M | 14.73% | |
| 3 | SIONSionna Therapeutics Inc | 197,072 | $8.1M | 8.02% | |
| 4 | RLAYRelay Therapeutics Inc | 901,457 | $7.6M | 7.54% | |
| 5 | CMPSCompass Pathways Plc | 819,692 | $5.7M | 5.59% | |
| 6 | PHVSPharvaris NV | 198,772 | $5.5M | 5.46% | |
| 7 | SEPNSepterna Inc | 194,544 | $5.4M | 5.36% | |
| 8 | ORKAOruka Therapeutics Inc | 118,524 | $3.6M | 3.55% | |
| 9 | IKTInhibikase Therapeutics Inc | 1,750,000 | $3.6M | 3.55% | |
| 10 | ALLOAllogene Therapeutics Inc | 2,546,129 | $3.5M | 3.45% | |
| 11 | LONALeonaBio Inc | 393,701 | $3.0M | 2.95% | |
| 12 | MLTXMoonLake Immunotherapeutics | 175,734 | $2.3M | 2.29% | |
| 13 | ORICOric Pharmaceuticals Inc | 267,059 | $2.2M | 2.16% | |
| 14 | VRCAVerrica Pharmaceuticals Inc | 235,779 | $2.0M | 1.94% | |
| 15 | TYRATyra Biosciences Inc | 74,465 | $2.0M | 1.94% | |
| 16 | SRZNSurrozen Inc | 385,178 | $1.9M | 1.87% | |
| 17 | TNYATenaya Therapeutics Inc | 2,000,000 | $1.4M | 1.41% | |
| 18 | KLRSKalaris Therapeutics Inc | 139,901 | $1.2M | 1.17% | |
| 19 | DMACDiamedica Therapeutics Inc | 95,359 | $759K | 0.75% |
Sector Breakdown
Healthcare0.0% ($1.4891810776265658e+62T)
Financial Services0.0% ($26.6M)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 13, 2026 | $101.1M | 19 |
Fund Information
Kalehua Capital Management LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $101.1M across 19 holdings. The largest position is Alpha Architect 1-3 Month Box Etf (BOXX), representing 26.3% of the portfolio. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.